MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 4, 2008; DOI: 10.1124/mol.107.042820


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.042820v1
74/5/1407    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Bertrand, D.
Right arrow Articles by Gopalakrishnan, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bertrand, D.
Right arrow Articles by Gopalakrishnan, M.


Received for publication October 19, 2007.
Revised July 8, 2008.
Accepted for publication August 1, 2008.

Positive Allosteric Modulation of the {alpha}7 nAChR: Ligand Interactions with Distinct Binding Sites and Evidence for a Prominent Role of the M2-M3 Segment 7 nAChR: Ligand Interactions with Distinct Binding Sites and Evidence for a Prominent Role of the M2-M3 Segment

Daniel Bertrand 1*, Sonia Bertrand 1, Steven Cassar 2, Earl Gubbins 2, Jinhe Li 2, Murali Gopalakrishnan 2

1 Dpt of Neuroscience 2 Abbott Laboratories

* Address correspondence to: E-mail: daniel.bertrand{at}medecine.unige.ch

Abstract

The {alpha}7 nicotinic acetylcholine receptor (nAChR), a homopentameric, rapidly activating and desensitizing ligand-gated ion channel with relatively high degree of calcium permeability, is expressed in the mammalian central nervous system including in regions associated with cognitive processing. Selective agonists targeted the {alpha}7 nAChR have shown efficacy in animal models of cognitive dysfunction. Use of positive allosteric modulators selective for the {alpha}7 receptor is another strategy that is envisaged in the design of active compounds aiming at improving cognitive and sensory gating dysfunction. The recent discovery of novel positive allosteric modulators such as the NS-1738 and PNU-120596 that are selective for the {alpha}7 nAChRs but display significant phenotypic differences in their profile of allosteric modulation suggests that these molecules may act at different sites on the receptor. Taking advantage of the possibility to obtain functional receptors by the fusion of proteins domains from the {alpha}7 and the 5-HT3 receptor, we examined the structural determinants required for positive allosteric modulation. This strategy revealed that the extracellular N-terminal domain of {alpha}7 plays a critical role in allosteric modulation by NS-1738. In addition, {alpha}7-5HT3 chimeras harboring the M2-M3 segment showed that spontaneous activity in response to NS-1738, which confirmed the critical contribution of this small extracellular segment in the receptor gating. In contrast to NS-1738, positive allosteric modulation by PNU-120596 could not be restored in the {alpha}7-5HT3 chimeras, but was selectively observed in the reverse 5HT3- {alpha}7 chimera. Altogether, these data illustrate the existence of distinct allosteric binding sites with specificity of different profiles of allosteric modulators, and open new possibilities to investigate the {alpha}7 receptor function.


Key words: Nicotinic cholinergic, Ion channel regulation, Synaptic plasticity





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics